Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ruvise

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

- PMLiVE

Novartis and Google to fund ‘robotic pill’ maker

Firms sign up to Rani Therapeutics’ new drug delivery system

- PMLiVE

EMA prepares to launch medical literature monitoring service

Will screen documents for 400 active substance groups

- PMLiVE

Afinitor set for filing this year in neuroendocrine cancer

Novartis drug is already approved for breast and renal cancers

- PMLiVE

Pfizer maintains lead in top CNS drug sales – just

But Biogen is looking to take the top spot next year as its MS portfolio grows

- PMLiVE

Novartis biosimilar blocked by US court

Swiss firm’s Neupogen copy has its injunction upheld at appeal

- PMLiVE

EMA clears Novartis’ lung cancer drug Zykadia

First treatment option in Europe for patients with ALK-postitive NSCLC

EU flag

EMA to stop ‘revolving doors’ committee members

Comes nearly five years after its former director left for a pharma service firm

- PMLiVE

Heart drug sales continue downward spiral

But revenue has stabilised after a tough three years of patent expiries

- PMLiVE

Pfizer falls as strong dollar and generic erosion bites

First quarter results beat analysts’ estimates but sales still sliding

- PMLiVE

Novartis still hungry after absorbing GSK oncology

CEO says firm is looking to strengthen pipelines in its three businesses

- PMLiVE

Pfizer breast cancer drug shines in latest trial

Study with Ibrance stopped early because of its success

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links